Benefits of Retained Insulin for Good Health in Diabetes
Official title: Understanding the Impact of Endogenous Insulin Secretion on Clinical Outcomes in Type 1 Diabetes and the Optimal Approach to C-peptide Measurement for Outcome Prediction
Run by Royal Devon and Exeter NHS Foundation Trust · NCT07828626 · Data updated 2026-11-12
This study tests whether preserving or restoring a person’s own insulin production can improve quality of life and blood sugar control for people who need insulin to manage diabetes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 700 (estimated) |
| Sponsor | Royal Devon and Exeter NHS Foundation Trust Academic / other |
| Locations | 4 sites (Truro, Cornwall and 3 other locations) |
| Status | Recruiting |
| Started | October 31, 2025 |
| Main results expected | April 30, 2027 |
| Study ends | June 30, 2027 |
| Registry record updated | September 18, 2026 |
| Trial ID | NCT07828626 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with insulin-treated diabetes who participated in the StartRight study or have Type 1 diabetes with known C-peptide or recent islet antibodies.
✕Probably not a fit
Patients without preserved or measurable endogenous insulin or those with advanced renal impairment may have limited or no observed benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study extends the StartRight cohort to explore how retained or restored endogenous insulin (as measured by C-peptide) relates to quality of life and clinical outcomes in adults with insulin-treated diabetes. It will collect additional data through remote or in-person visits and analyze both pragmatic and non-pragmatic C-peptide measures to identify which best correlate with benefit. The research includes adults with Type 1 diabetes and those with insulin-treated diabetes, and it aims to clarify long-term advantages and how to measure them efficiently in real-world settings. The study builds on a large, ongoing prospective cohort and may inform decisions about the use of therapies that aim to preserve or restore insulin secretion.
Why it matters
Potential benefit: If successful, the study could help identify which patients are most likely to benefit from real-world strategies to preserve or restore insulin production and improve treatment decisions.
How similar studies have gone: Prior research suggests some people with Type 1 diabetes retain small amounts of insulin, but long-term benefits and best measures remain uncertain.
Who can join: the full rules
Show full inclusion / exclusion criteria
ARM 1 Inclusion Criteria: * Previously recruited to the StartRight study (NCT03737799) with consent to be contacted for further research * Clinical diagnosis of diabetes \& Insulin treated * Able and willing to provide informed consent/assent. * Aged 18 years or older. ARM 2 Inclusion Criteria: * Clinical diagnosis of Type 1 diabetes * Known C-peptide, measured as part of previous research or as part of diabetes clinical care OR Where C-peptide is not measured, participant must be within 7 years of diagnosis and have at least 1 positive islet antibody, measured at any time since diabetes diagnosis. * Where measured C-peptide is \>600pmol/L, previous positive islet autoantibodies. * Able and willing to provide informed consent * Aged 18 years or older Exclusion Criteria: \- Renal failure defined by eGFR \<30mL/min/1.73 m²
Where it's running
-
Diabetes and Endocrine Centre
Truro, Cornwall, United Kingdom Recruiting -
NIHR Exeter Clinical Research Facility
Exeter, Devon, United Kingdom Recruiting -
D1 Wolfson Centre Research and Development
Bath, United Kingdom Recruiting -
Clinical Research Centre
Bristol, United Kingdom Recruiting
Study contacts
- Study coordinator: BRIGHT Study Research Team
- Email: rduh.brightstudy@nhs.net
- Phone: +44 1392408181
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Three-stage CGM integration program for older adults with insulin-dependent diabetes
A program with three CGM-focused training sessions is being tested to see if it helps older adults using insulin wear CGMs more and manage their glucose better compared with standard CGM training.
-
iLet Bionic Pancreas started through primary care for adults on insulin
This project will test whether starting the iLet Bionic Pancreas through primary care helps adults with insulin-treated type 1 or type 2 diabetes lower their A1c more than routine care over 13 weeks.
-
Continuous temperature monitoring of the feet with connected insoles and a smartphone app in adults with diabetes at high risk
This trial tests whether the Solsius SelfCare system can reliably flag pre-ulcer foot changes in adults with diabetes by detecting temperature differences between feet for at least two consecutive days.
-
RIGHTEST iFree 2 CGM system for better diabetes control in adults on insulin
A real-time CGM system is tested to see if it improves blood sugar control for adults with type 1 or type 2 diabetes on insulin, compared with finger-stick monitoring.
-
New virtual care pathway for older adults with chronic diseases
A teleconsultation-based care pathway for adults 60+ with hypertension, diabetes, or dyslipidemia to see if it’s feasible and cost-saving in Malaysian primary care compared with usual clinic visits.
-
Predictive CGM with App for people with type 1 or insulin-treated type 2 diabetes
This study tests whether using the Accu-Chek SmartGuide CGM with its Predict App can reduce fear of hypoglycemia and improve related behaviors and confidence in adults with type 1 or insulin-treated type 2 diabetes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.